{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:55:50Z","timestamp":1782561350626,"version":"3.54.5"},"reference-count":135,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Calcium channel blockers (CCBs), originally developed for cardiovascular indications, have gained attention for their therapeutic potential in neuropsychiatric, endocrine, and pain-related disorders. In neuropsychiatry, nimodipine and isradipine, both L-type CCBs, show mood-stabilizing and neuroprotective effects, with possible benefits in depression, bipolar disorder, and schizophrenia. In endocrinology, verapamil, a non-dihydropyridine L-type blocker, has been associated with the preservation of pancreatic \u03b2-cell function and reduced insulin dependence in diabetes. CCBs may also aid in managing primary aldosteronism and pheochromocytoma, particularly in patients with calcium signaling mutations. In pain medicine, \u03b12\u03b4 ligands and selective blockers of N-type and T-type channels demonstrate efficacy in neuropathic and inflammatory pain. However, their broader use is limited by challenges in central nervous system (CNS) penetration, off-target effects, and heterogeneous trial outcomes. Future research should focus on pharmacogenetic stratification, novel delivery platforms, and combination strategies to optimize repurposing of CCBs across disciplines.<\/jats:p>","DOI":"10.3390\/cells14141114","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:56:14Z","timestamp":1753084574000},"page":"1114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Potential of Calcium Channel Blockers in Neuropsychiatric, Endocrine and Pain Disorders"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4223-3170","authenticated-orcid":false,"given":"Aarish","family":"Manzar","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA"},{"name":"Department of Internal Medicine, Ziauddin Medical College, Karachi 75500, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9093-6998","authenticated-orcid":false,"given":"Aleksandar","family":"Sic","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Banh","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-1495","authenticated-orcid":false,"given":"Nebojsa Nick","family":"Knezevic","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA"},{"name":"Department of Anesthesiology, University of Illinois, Chicago, IL 60612, USA"},{"name":"Department of Surgery, University of Illinois, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Godfraind, T. (2017). Discovery and Development of Calcium Channel Blockers. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00286"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-94-009-7561-3_24","article-title":"Calcium Channel Blockers\/Historical Perspectives","volume":"Volume 18","author":"Morganroth","year":"1982","journal-title":"The Evaluation of Beta Blocker and Calcium Antagonist Drugs"},{"key":"ref_3","unstructured":"McKeever, R.G., Patel, P., and Hamilton, R.J. (2025, June 04). Calcium Channel Blockers, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482473\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium Channel Blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/17512433.2021.1894128","article-title":"Use of Calcium Channel Blockers in Dermatology: A Narrative Review","volume":"14","author":"Lo","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/070674379904400702","article-title":"Calcium Channel Blockers in Psychiatric Disorders: A Review of the Literature","volume":"44","author":"Hollister","year":"1999","journal-title":"Can. J. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"110031","DOI":"10.1016\/j.neuropharm.2024.110031","article-title":"L-Type Calcium Channel Regulation of Depression, Anxiety and Anhedonia-Related Behavioral Phenotypes Following Chronic Stress Exposure","volume":"257","author":"Nunes","year":"2024","journal-title":"Neuropharmacology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.amjmed.2020.05.039","article-title":"The Effect of Calcium Channel Blockers on Moderate or Severe Albuminuria in Diabetic, Hypertensive Patients","volume":"134","author":"Cativo","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_9","first-page":"89","article-title":"Can Amlodipine Improve the Pre-Ovulatory Follicle Blood Flow in Women with Polycystic Ovarian Syndrome?","volume":"20","author":"Faham","year":"2019","journal-title":"J. Reprod. Infertil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/1056-8727(95)80005-Y","article-title":"Effects of a Calcium Channel Blocker, Manidipine, on Insulin Sensitivity in Essential Hypertensives","volume":"9","author":"Iimura","year":"1995","journal-title":"J. Diabetes Complicat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/DMSO.S49767","article-title":"Effect of Calcium Channel Blockers on Incidence of Diabetes: A Meta-Analysis","volume":"6","author":"Noto","year":"2013","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0303-8467(96)00594-X","article-title":"Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy and Causalgia): Management with the Calcium Channel Blocker Nifedipine and\/or the Alpha-Sympathetic Blocker Phenoxybenzamine in 59 Patients","volume":"99","author":"Muizelaar","year":"1997","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"139B","DOI":"10.1016\/0002-9149(85)90622-8","article-title":"Calcium-Channel Blockers in the Treatment of Migraine","volume":"55","author":"Gelmers","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biopha.2012.10.006","article-title":"Calcium Channel Blockers Reduce Oxaliplatin-Induced Acute Neuropathy: A Retrospective Study of 69 Male Patients Receiving Modified FOLFOX6 Therapy","volume":"67","author":"Tatsushima","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Li, Y., Fan, Y., Sun, Y., Alolga, R.N., Xiao, P., and Ma, G. (2021). Antihypertensive Drug Use and the Risk of Depression: A Systematic Review and Network Meta-Analysis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.777987"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/s41380-022-01615-6","article-title":"Brain-Penetrant Calcium Channel Blockers Are Associated with a Reduced Incidence of Neuropsychiatric Disorders","volume":"27","author":"Colbourne","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/HYPERTENSIONAHA.116.08188","article-title":"Monotherapy with Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders","volume":"68","author":"Boal","year":"2016","journal-title":"Hypertension"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Stachowicz, K., and Sowa-Ku\u0107ma, M. (2022). The Treatment of Depression\u2014Searching for New Ideas. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.988648"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bdi.12143","article-title":"Pilot Investigation of Isradipine in the Treatment of Bipolar Depression Motivated by Genome-Wide Association","volume":"16","author":"Ostacher","year":"2014","journal-title":"Bipolar Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1017\/S1041610205001493","article-title":"A Double-Blind, Randomized Clinical Trial to Assess the Augmentation with Nimodipine of Antidepressant Therapy in the Treatment of \u201cVascular Depression\u201d","volume":"17","author":"Taragano","year":"2005","journal-title":"Int. Psychogeriatr."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wu, S., Zhang, Y., Lu, Y., Yin, Y., Yang, C., Tang, W., Song, T., Tao, X., and Wang, Q. (2025). Vascular Depression: A Comprehensive Exploration of the Definition, Mechanisms, and Clinical Challenges. Neurobiol. Dis., 211.","DOI":"10.1016\/j.nbd.2025.106946"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17425255.2019.1558206","article-title":"Applications of Calcium Channel Blockers in Psychiatry: Pharmacokinetic and Pharmacodynamic Aspects of Treatment of Bipolar Disorder","volume":"15","author":"Dubovsky","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-020-00135-y","article-title":"Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia","volume":"7","author":"Lintunen","year":"2021","journal-title":"NPJ Schizophr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jad.2022.06.040","article-title":"Allopurinol, Dipyridamole and Calcium Channel Blockers in the Treatment of Bipolar Disorder\u2014A Nationwide Cohort Study","volume":"313","author":"Lintunen","year":"2022","journal-title":"J. Affect. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115281","DOI":"10.1016\/j.psychres.2023.115281","article-title":"A Pilot Pharmacogenetic Study of Calcium Channel Blocker Treatment of Bipolar Mania","volume":"326","author":"Li","year":"2023","journal-title":"Psychiatry Res."},{"key":"ref_26","unstructured":"(2025, June 16). Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder. Available online: https:\/\/trial.medpath.com\/clinical-trial\/5eec1264f90cd7d6\/evaluating-isradipine-cognitive-enhancement-schizophrenia."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41386-025-02062-x","article-title":"Validation of L Type Calcium Channel Blocker Amlodipine as a Novel ADHD Treatment through Cross Species Analysis, Drug Target Mendelian Randomization, and Clinical Evidence from Medical Records","volume":"50","author":"Baukmann","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group STEADY-PD III Investigators (2020). Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann. Intern. Med., 172, 591\u2013598.","DOI":"10.7326\/M19-2534"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"P2-039","DOI":"10.1212\/WNL.90.15_supplement.P2.039","article-title":"A Phase 3 Study of Isradipine as a Disease Modifying Agent in Patients with Early Parkinson\u2019s Disease (STEADY-PD III): Baseline Characteristics and Study Update (P2.039)","volume":"90","author":"Simuni","year":"2018","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zheng, S., Wang, Y., Tang, S., Guo, Y., Ma, D., and Jiang, X. (2025). Mechanism of Nimodipine in Treating Neurodegenerative Diseases: In Silico Target Identification and Molecular Dynamic Simulation. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1549953"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lin, W., Lin, C.L., Hsu, C.Y., and Wei, C.Y. (2019). Flunarizine Induced Parkinsonism in Migraine Group: A Nationwide Population-Based Study. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01495"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"120526","DOI":"10.1016\/j.jns.2022.120526","article-title":"Permanent Non-Progressive Cinnarizine and Flunarizine-Induced Parkinsonism: An Under-Recognized Tardive Syndrome in the Elderly?","volume":"444","author":"Calzetti","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1212\/WNL.0000000000000473","article-title":"Paroxysmal Features Responding to Flunarizine in a Child with Rapid-Onset Dystonia-Parkinsonism","volume":"82","author":"Fornarino","year":"2014","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e29413","DOI":"10.1097\/MD.0000000000029413","article-title":"Alternating Hemiplegia of Childhood: A Distinct Clinical Entity and ATP1A3-Related Disorders: A Narrative Review","volume":"101","author":"Pavone","year":"2022","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Serafini, G., Adavastro, G., Pardini, M., Brondino, N., and Amore, M. (2024). Early-Life Adversities and Epigenetic Modifications: The Impact on Brain Development, Synaptic Function, and Stress Response. Biol. Psychiatry Glob. Open Sci.","DOI":"10.1016\/j.bpsgos.2025.100560"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Francis, A., McKibben, L.A., and Dwivedi, Y. (2025). Early-Life Adversity-Induced Epigenetic Reprogramming of Prefrontal Cortex in Rats Subjected to Maternal Separation. Biol. Psychiatry Glob. Open Sci., 5.","DOI":"10.1016\/j.bpsgos.2025.100487"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ye, C., Wang, T., Wang, H., Lian, G., and Xie, L. (2024). Causal Relationship between Genetic Proxies for Calcium Channel Blockers and the Risk of Depression: A Drug-Target Mendelian Randomization Study. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1377705"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhang, K., Gao, H., and Chen, M. (2023). Association of Antihypertensive Drugs with COVID-19 Outcomes: A Drug-Target Mendelian Randomization Study. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1224737"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fan, B., and Zhao, J.V. (2024). Genetic Proxies for Antihypertensive Drugs and Mental Disorders: Mendelian Randomization Study in European and East Asian Populations. BMC Med., 22.","DOI":"10.1186\/s12916-023-03218-6"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s001250050706","article-title":"The Pancreatic Beta-Cell as a Fuel Sensor: An Electrophysiologist\u2019s Viewpoint","volume":"40","author":"Rorsman","year":"1997","journal-title":"Diabetologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.2337\/db07-0991","article-title":"Voltage-Gated Ion Channels in Human Pancreatic \u03b2-Cells: Electrophysiological Characterization and Role in Insulin Secretion","volume":"57","author":"Braun","year":"2008","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.2337\/diabetes.53.suppl_3.S113","article-title":"Metabolic Regulation of the Pancreatic Beta-Cell ATP-Sensitive K+ Channel: A Pas de Deux","volume":"53","author":"Tarasov","year":"2004","journal-title":"Diabetes"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.2337\/db06-0868","article-title":"Nutrient Control of Insulin Secretion in Isolated Normal Human Islets","volume":"55","author":"Henquin","year":"2006","journal-title":"Diabetes"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/db11-0955","article-title":"Preventing \u03b2-Cell Loss and Diabetes with Calcium Channel Blockers","volume":"61","author":"Xu","year":"2012","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.2337\/db23-0256","article-title":"Verapamil Prevents Decline of IGF-I in Subjects with Type 1 Diabetes and Promotes \u03b2-Cell IGF-I Signaling","volume":"72","author":"Xu","year":"2023","journal-title":"Diabetes"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Sun, P., Wang, T., Chen, K., Zhu, W., and Wang, H. (2015). Inhibition of Calcium Influx Reduces Dysfunction and Apoptosis in Lipotoxic Pancreatic \u03b2-Cells via Regulation of Endoplasmic Reticulum Stress. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132411"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mce.2007.04.004","article-title":"Involvement of Ca2+-Mediated Apoptotic Signals in Palmitate-Induced MIN6N8a Beta Cell Death","volume":"272","author":"Choi","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.1152\/ajpendo.90525.2008","article-title":"Effects of Palmitate on ER and Cytosolic Ca2+ Homeostasis in Beta-Cells","volume":"296","author":"Gwiazda","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12986-021-00597-6","article-title":"Calcium Channel Blockers Do Not Protect against Saturated Fatty Acid-Induced ER Stress and Apoptosis in Human Pancreatic \u03b2-Cells","volume":"18","year":"2021","journal-title":"Nutr. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s13300-021-01145-4","article-title":"The Effect of Verapamil on TXNIP Gene Expression, GLP1R mRNA, FBS, HbA1c, and Lipid Profile in T2DM Patients Receiving Metformin and Sitagliptin","volume":"12","author":"Malayeri","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","article-title":"Verapamil and \u03b2-cell Function in Adults with Recent-Onset Type 1 Diabetes","volume":"24","author":"Ovalle","year":"2018","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41467-022-28826-3","article-title":"Exploratory Study Reveals Far Reaching Systemic and Cellular Effects of Verapamil Treatment in Subjects with Type 1 Diabetes","volume":"13","author":"Xu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1210\/jc.2016-3778","article-title":"Verapamil Use Is Associated with Reduction of Newly Diagnosed Diabetes Mellitus","volume":"102","author":"Yin","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.amjcard.2006.04.030","article-title":"Predictors of Development of Diabetes Mellitus in Patients with Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])","volume":"98","author":"Cohen","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ahj.2005.05.024","article-title":"Blood Pressure Control and Cardiovascular Outcomes in High-Risk Hispanic Patients\u2014Findings from the International Verapamil SR\/Trandolapril Study (INVEST)","volume":"151","author":"Aranda","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diabres.2016.01.021","article-title":"Calcium Channel Blocker Use Is Associated with Lower Fasting Serum Glucose among Adults with Diabetes from the REGARDS Study","volume":"115","author":"Khodneva","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2124443","DOI":"10.1001\/jamanetworkopen.2021.24443","article-title":"Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly with Insulin Secretagogues","volume":"4","author":"Nam","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e4063","DOI":"10.1210\/clinem\/dgac436","article-title":"A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes","volume":"107","author":"Wang","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2023.2064","article-title":"Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial","volume":"329","author":"Forlenza","year":"2023","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Arefanian, H., Koti, L., Sindhu, S., Ahmad, R., Al Madhoun, A., and Al-Mulla, F. (2023). Verapamil Chronicles: Advances from Cardiovascular to Pancreatic \u03b2-Cell Protection. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1322148"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative Management of the Pheochromocytoma Patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Fang, F., Ding, L., He, Q., and Liu, M. (2020). Preoperative Management of Pheochromocytoma and Paraganglioma. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.586795"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/edrv-15-3-356","article-title":"Evolving Concepts in the Pathophysiology, Diagnosis, and Treatment of Pheochromocytoma","volume":"15","author":"Bravo","year":"1994","journal-title":"Endocr. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0022-5347(01)61762-2","article-title":"Successful Outcomes in Pheochromocytoma Surgery in the Modern Era","volume":"161","author":"Ulchaker","year":"1999","journal-title":"J. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2044.2005.04156.x","article-title":"The Effect of Calcium Channel Blockers on Outcome Following the Surgical Treatment of Phaeochromocytomas and Paragangliomas","volume":"60","author":"Lebuffe","year":"2005","journal-title":"Anaesthesia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.surg.2012.08.023","article-title":"Utility of Oral Nicardipine and Magnesium Sulfate Infusion during Preparation and Resection of Pheochromocytomas","volume":"152","author":"Siddiqi","year":"2012","journal-title":"Surgery"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.surg.2014.08.022","article-title":"Both Preoperative Alpha and Calcium Channel Blockade Impact Intraoperative Hemodynamic Stability Similarly in the Management of Pheochromocytoma","volume":"156","author":"Brunaud","year":"2014","journal-title":"Surgery"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-60-5-896","article-title":"Therapeutic Effect of Calcium Channel Blockade in Primary Aldosteronism","volume":"60","author":"Nadler","year":"1985","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_70","first-page":"I-191","article-title":"Calcium Channel Blockade with Nifedipine in Primary Aldosteronism","volume":"8","author":"Bravo","year":"1986","journal-title":"Hypertension"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"88S","DOI":"10.1093\/ajh\/1.3.88S","article-title":"The Absence of Long-Term Therapeutic Effect of Calcium Channel Blockade in the Primary Aldosteronism of Adrenal Adenomas","volume":"1","author":"Bursztyn","year":"1988","journal-title":"Am. J. Hypertens."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","article-title":"Pharmacological Treatment of Aldosterone Excess","volume":"154","author":"Deinum","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e162468","DOI":"10.1172\/jci.insight.162468","article-title":"Isradipine Therapy in Cacna1dIle772Met\/+ Mice Ameliorates Primary Aldosteronism and Neurologic Abnormalities","volume":"8","author":"Dinh","year":"2023","journal-title":"JCI Insight"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/en.2013-1944","article-title":"Pharmacology and Pathophysiology of Mutated KCNJ5 Found in Adrenal Aldosterone-Producing Adenomas","volume":"155","author":"Tauber","year":"2014","journal-title":"Endocrinology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wang, F., Ma, X., Tong, A., Zhang, Y., Wen, J., and Li, Y. (2020). The Effects of Different Calcium Channel Blockers on Aldosterone-Producing Adenoma Cells. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00260"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19336950.2020.1761171","article-title":"A de novo CACNA1D missense mutation in a patient with congenital hyperinsulinism, primary hyperaldosteronism and hypotonia","volume":"14","year":"2020","journal-title":"Channels"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cell.2009.09.025","article-title":"Gabapentin receptor \u03b12\u03b4-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis","volume":"139","author":"Eroglu","year":"2009","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","article-title":"The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin","volume":"29","author":"Bauer","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freynhagen","year":"2005","journal-title":"Pain"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2020.56.2.3100504","article-title":"Mirogabalin besylate in the treatment of neuropathic pain","volume":"56","author":"Burgess","year":"2020","journal-title":"Drugs Today"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","article-title":"Mirogabalin for the management of postherpetic neuralgia: A randomized, double-blind, placebo-controlled phase 3 study in Asian patients","volume":"160","author":"Kato","year":"2019","journal-title":"Pain"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamadermatol.2024.3410","article-title":"Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial","volume":"160","author":"Zhang","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Pan, T., Ma, J., Li, Y., Wang, K., Jiang, C., Zhang, Y., Liu, J., Du, R., Zhang, W., and  Bian, F. (2025). Rapid Onset of Pain Relief with Crisugabalin in Patients with Diabetic Peripheral Neuropathic Pain: Findings from a Multicenter, Randomized, Double-Blind, Controlled Study. Pain Ther.","DOI":"10.1007\/s40122-025-00745-3"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Gou, X., Liu, Y., Ye, Q., He, L., Chen, Y., Dong, Y., Meng, Q., Shi, Z., Li, Y., and Lu, Y. (2025). Crisugabalin, a ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels, exhibits no obvious abuse potential in rodents. Pharmacol. Biochem. Behav., 252.","DOI":"10.1016\/j.pbb.2025.174015"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"124396","DOI":"10.1016\/j.jchromb.2024.124396","article-title":"Quantification of crisugabalin (HSK16149) in biological matrix by LC-MS\/MS method: An application to rat pharmacokinetic and tissue distribution studies","volume":"1251","author":"Wang","year":"2025","journal-title":"J. Chromatogr. B"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e31105","DOI":"10.1016\/j.heliyon.2024.e31105","article-title":"A comprehensive review on ziconotide","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"ref_88","unstructured":"Wie, C.S., and Derian, A. (2025, June 29). Ziconotide, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459151\/."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bpa.2023.02.003","article-title":"Intrathecal drug delivery in the management of chronic pain","volume":"37","author":"Rauck","year":"2023","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e177429","DOI":"10.1172\/JCI177429","article-title":"C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models","volume":"135","author":"Tang","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/bph.16309","article-title":"An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain","volume":"181","author":"Kutzsche","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.37349\/emed.2023.00126","article-title":"N-type calcium channel blockers: A new approach towards the treatment of chronic neuropathic pain","volume":"4","author":"Choudhary","year":"2023","journal-title":"Explor. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1200\/JCO.18.01567","article-title":"Comparative Efficacy of Therapeutics for Chronic Cancer Pain: A Bayesian Network Meta-Analysis","volume":"37","author":"Huang","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system\u201440 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Shibata, Y. (2022). Migraine Pathophysiology Revisited: Proposal of a New Molecular Theory of Migraine Pathophysiology and Headache Diagnostic Criteria. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113002"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/00207454.2022.2079503","article-title":"Ratanasampil is more effective than flunarizine in relieving migraine","volume":"133","author":"Zhu","year":"2023","journal-title":"Int. J. Neurosci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","article-title":"European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention\u2014Part 2: Flunarizine","volume":"24","author":"Deligianni","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chang, Y.-S., and Choi, J.H. (2025). Potential Benefits of Flunarizine in Patients with Sudden Sensorineural Hearing Loss with Incomplete Recovery Following Conventional Steroid Treatment: A Retrospective Analysis. Medicina, 61.","DOI":"10.3390\/medicina61040769"},{"key":"ref_99","unstructured":"Kumar, A., and Kadian, R. (2025, June 29). Migraine Prophylaxis, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507873\/."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the Trigeminal System in Migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40120-025-00785-z","article-title":"From Headache to Heart Health: Investigating the Migraine\u2013Cardiovascular Disease Connection","volume":"14","author":"Tana","year":"2025","journal-title":"Neurol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e189308","DOI":"10.1172\/JCI189308","article-title":"The N-type calcium channel rises from the ashes","volume":"135","author":"Gandini","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_103","first-page":"e12001","article-title":"Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study","volume":"6","author":"Kutzsche","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Sanner, K. (2025). Facilitation of CaV3.2 channel gating in pain pathways reveals a novel mechanism of serum-induced hyperalgesia. bioRxiv.","DOI":"10.1101\/2025.01.03.631165"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trsl.2021.01.002","article-title":"Targeting T-type\/CaV3.2 channels for chronic pain","volume":"234","author":"Cai","year":"2021","journal-title":"Transl. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00702-019-02088-8","article-title":"Visceral pain from colon and rectum: The mechanotransduction and biomechanics","volume":"127","author":"Feng","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"105222","DOI":"10.1016\/j.jbspin.2021.105222","article-title":"Chronic pain and neuroinflammation","volume":"88","author":"Bertin","year":"2021","journal-title":"Jt. Bone Spine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41392-024-01845-w","article-title":"Pathology of pain and its implications for therapeutic interventions","volume":"9","author":"Cao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00424-023-02891-z","article-title":"The T-type calcium channelosome","volume":"476","author":"Weiss","year":"2024","journal-title":"Pflugers Arch."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chakraborty, R., Hu, H., Darido, C., Vickery, K., and Ranganathan, S. (2021). ML218 HCl Is More Efficient Than Capsaicin in Inhibiting Bacterial Antigen-Induced Cal 27 Oral Cancer Cell Proliferation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212559"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1021\/cn200090z","article-title":"The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson\u2019s Disease","volume":"2","author":"Xiang","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/j.pain.0000000000000774","article-title":"Dorsal root ganglion neurons become hyperexcitable and increase expression of voltage-gated T-type calcium channels (Cav3.2) in paclitaxel-induced peripheral neuropathy","volume":"158","author":"Li","year":"2017","journal-title":"Pain"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"176919","DOI":"10.1016\/j.ejphar.2024.176919","article-title":"ML218 modulates calcium binding protein, oxidative stress, and inflammation during ischemia-reperfusion brain injury in mice","volume":"982","author":"Sharma","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1111\/bph.15498","article-title":"The T-type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity","volume":"178","author":"Harding","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bcp.2014.03.015","article-title":"A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats","volume":"89","author":"Jarvis","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/j.pain.0000000000000263","article-title":"A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain","volume":"156","author":"Ziegler","year":"2015","journal-title":"Pain"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"176416","DOI":"10.1016\/j.ejphar.2024.176416","article-title":"Effect of ABT-639 on Cav3.2 channel activity and its analgesic actions in mouse models of inflammatory and neuropathic pain","volume":"967","author":"Antunes","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/jns.12080_2","article-title":"Z944: A first in class T-type calcium channel modulator for the treatment of pain","volume":"19","author":"Lee","year":"2014","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/bph.13789","article-title":"Calcium channel modulation as a target in chronic pain control","volume":"175","author":"Patel","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Cardoso, F.C., Marliac, M.A., Geoffroy, C., Schmit, M., Bispat, A., Lewis, R.J., Tuck, K.L., and Duggan, P.J. (2020). The neuronal calcium ion channel activity of constrained analogues of MONIRO-1. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115655"},{"key":"ref_121","first-page":"3287","article-title":"A Dual Sodium Channel and Calcium Channel inhibitor Ameliorates Ocular Pain in a Murine Dry Eye Disease Model","volume":"64","author":"Naderi","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e48118","DOI":"10.7554\/eLife.48118","article-title":"Novel charged sodium and calcium channel inhibitor active against neurogenic inflammation","volume":"8","author":"Lee","year":"2019","journal-title":"eLife"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lfs.2017.06.018","article-title":"Synergistic antinociceptive effect of a calcium channel blocker and a TRPV1 blocker in an acute pain model in mice","volume":"182","author":"Palhares","year":"2017","journal-title":"Life Sci."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Gao, N., Li, M., Wang, W., Liu, Z., and Guo, Y. (2024). The dual role of TRPV1 in peripheral neuropathic pain: Pain switches caused by its sensitization or desensitization. Front. Mol. Neurosci., 17.","DOI":"10.3389\/fnmol.2024.1400118"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3332\/ecancer.2018.886","article-title":"ReDO_DB: The Repurposing Drugs in Oncology Database","volume":"12","author":"Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug Repurposing: Progress, Challenges and Recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jacbts.2022.12.012","article-title":"Off-Label Use vs Off-Label Marketing: Part 2: Off-Label Marketing\u2014Consequences for Patients, Clinicians, and Researchers","volume":"8","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can You Teach Old Drugs New Tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Agrawal, Y.O., Husain, M., Patil, K.D., Sodgir, V., Patil, T.S., Agnihotri, V.V., Mahajan, H.S., Sharma, C., Ojha, S., and Goyal, S.N. (2022). Verapamil Hydrochloride Loaded Solid Lipid Nanoparticles: Preparation, Optimization, Characterisation, and Assessment of Cardioprotective Effect in Experimental Model of Myocardial Infarcted Rats. Biomed. Pharmacother., 154.","DOI":"10.1016\/j.biopha.2022.113429"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jconrel.2023.03.007","article-title":"Microneedle-Mediated Delivery of Ziconotide-Loaded Liposomes Fused with Exosomes for Analgesia","volume":"356","author":"Song","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1111\/bcp.14327","article-title":"Me-Too Pharmaceutical Products: History, Definitions, Examples, and Relevance to Drug Shortages and Essential Medicines Lists","volume":"86","author":"Aronson","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"103985","DOI":"10.1016\/j.drudis.2024.103985","article-title":"The Present State and Challenges of Active Learning in Drug Discovery","volume":"29","author":"Wang","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_133","first-page":"100352","article-title":"Safety and Prescribing Recommendations for Verapamil in Newly Diagnosed Pediatric Type 1 Diabetes (T1D): The CLVer Experience","volume":"36","author":"Ekhlaspour","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/picr.picr_70_24","article-title":"Drug Repurposing: Clinical Practices and Regulatory Pathways","volume":"16","author":"Saranraj","year":"2025","journal-title":"Perspect. Clin. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacbts.2022.12.011","article-title":"Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use\u2014Patient Harms and Prescriber Responsibilities","volume":"8","year":"2023","journal-title":"JACC Basic Transl. Sci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/14\/1114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:50Z","timestamp":1760033570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/14\/1114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":135,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cells14141114"],"URL":"https:\/\/doi.org\/10.3390\/cells14141114","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]}}}